Literature DB >> 14981760

Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.

F Xavier López-Labrador1, Xiao-Song He, Marina Berenguer, Ramsey C Cheung, Fernando González-Candelas, Teresa L Wright, Harry B Greenberg.   

Abstract

Hepatitis C virus (HCV) variation in specific T-cell epitopes may represent a mechanism of viral persistence in chronic infection. We examined the HCV non-structural protein 3 (NS3), including the immunologically relevant epitopes HCV NS3-2 KLVALGINAV (human leukocyte antigen [HLA]-A2-restricted) and HCV NS3-1391 LIFCHSKKK (HLA-A3-restricted), in 22 HLA-A2+ patients with chronic infection. Significant amino acid variation was found in HCV NS3-2 epitope sequences when compared to the HCV-1 prototype virus. Six of the nine different HCV NS3-2 peptide variants were identified in patients with HCV NS3-2-specific CD8+ cells, detected with an HLA-A2 tetramer made with the HCV-1 prototype peptide. Phylogenetic analysis, including HCV reference sequences other than HCV-1, suggested however that most of the variations in the HCV NS3-2 epitope could be related to genetic heterogeneity between HCV reference subtypes. Variation was less common when comparing HCV NS3-2 epitope sequences from the clinical isolates to the most-closely related HCV reference subtype in each case. Some subtype-independent variations were found in epitopic residues probably important for T-cell receptor interaction. In contrast, no significant variation was found in HLA primary anchor sites, flanking regions, or in the contiguous HLA A3-restricted CD8+ T-cell epitope. Ongoing variation was not evident in two selected patients with follow-up. In conclusion, (i) the HCV NS3-2 epitope is not conserved between different HCV strains/subtypes, and (ii) an HLA-A2 tetramer loaded with the HCV-1 prototype NS3-2 peptide may still detect NS3-specific CD8+ cells in some patients with variant viruses. These data may be useful to improve T-cell assays using HCV NS3 peptides, taking into account the genetic diversity of this virus. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981760     DOI: 10.1002/jmv.20036

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.

Authors:  Qian Yu; Li Zhang; Lichen Ouyang; Yeli Gong; Zhihui Liang; Guanxin Shen; Xiufang Weng; Xiongwen Wu
Journal:  Immunogenetics       Date:  2012-12-12       Impact factor: 2.846

2.  Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.

Authors:  Matthias Wölfl; Alleluiah Rutebemberwa; Timothy Mosbruger; Qing Mao; Hong-mei Li; Dale Netski; Stuart C Ray; Drew Pardoll; John Sidney; Alessandro Sette; Todd Allen; Thomas Kuntzen; Daniel G Kavanagh; Jürgen Kuball; Philip D Greenberg; Andrea L Cox
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

3.  Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients.

Authors:  F Xavier López-Labrador; Lorna Dove; Chee-Kin Hui; Yume Phung; Michael Kim; Marina Berenguer; Teresa L Wright
Journal:  Virus Res       Date:  2007-06-29       Impact factor: 3.303

4.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

5.  Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system.

Authors:  Vaishaali Natarajan; Camille R Simoneau; Ann L Erickson; Nathan L Meyers; Jody L Baron; Stewart Cooper; Todd C McDevitt; Melanie Ott
Journal:  Open Biol       Date:  2022-03-02       Impact factor: 6.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.